Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from tenofovir disoproxil fumarate to tenofovir alafenamide versus abacavir in HIV patients with TDF-associated eGFR decline
NL-OMON46033Phase 3Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tenofovir alafenamide and abacavir in human immunodeficiency virus infection (HIV), sponsored by Erasmus MC. Primary endpoint: Recovery of renal dysfunction at week 48. Started Oct 2016; status: active, not recruiting.
02
Drugs
tenofovir alafenamideabacavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON46033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46033.